Skip to content

Study · Randomized controlled trial · n = 29 · 2008

2 results

Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome.

Festen DA, Wevers M, Lindgren AC, Böhm B, Otten BJ, Wit JM, Duivenvoorden HJ, Hokken-Koelega AC

Clinical endocrinology19 Nov 2007Cited by 96 (Europe PMC)

PMID18031326 (opens in a new tab)DOI10.1111/j.1365-2265.2007.03126.x (opens in a new tab)PepBankPUB-18031326
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In infants with Prader-Willi syndrome, mental development changed by +9.3% with GH versus -2.9% in controls (P < 0.05).

    In plain wordsIn infants with Prader-Willi syndrome, GH improved mental development compared with untreated controls.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseMental development change
    Study

    n = 29

    Comparator
    Non-GH-treated control
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    1 mg/m(2)/day · 12 monthsAs given in this study (human).

    Measurements

    Mental development change
    9.3%
    GH median, IQR -5.3 to 13.3
    Mental development change
    −2.9%
    control median, IQR -8.1 to 4.9

    Source sentences

    Summary
    Both mental and motor development improved significantly during the first year of study in the GH group vs. the control group: median (IQR) change was +9.3% (-5.3 to 13.3) vs.-2.9% (-8.1 to 4.9) (P < 0.05) in mental development and +11.2% (-4.9 to 22.5) vs.-18.5% (-27.9 to 1.8) (P < 0.05) in motor d…
    2 context sentences
    Summary · context
    Twenty-nine of them were randomized into a GH group (n = 15) receiving 1 mg/m(2)/day GH or a non-GH-treated control group (n = 14).
    Summary · context
    At baseline and after 12 months of follow-up, analysis with Bayley Scales of Infant Development II (BSID-II) was performed.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In infants with Prader-Willi syndrome, motor development changed by +11.2% with GH versus -18.5% in controls (P < 0.05).

    In plain wordsIn infants with Prader-Willi syndrome, GH improved motor development compared with untreated controls.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseMotor development change
    Study

    n = 29

    Comparator
    Non-GH-treated control
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    1 mg/m(2)/day · 12 monthsAs given in this study (human).

    Measurements

    Motor development change
    11.2%
    GH median, IQR -4.9 to 22.5
    Motor development change
    −18.5%
    control median, IQR -27.9 to 1.8

    Source sentences

    Summary
    Both mental and motor development improved significantly during the first year of study in the GH group vs. the control group: median (IQR) change was +9.3% (-5.3 to 13.3) vs.-2.9% (-8.1 to 4.9) (P < 0.05) in mental development and +11.2% (-4.9 to 22.5) vs.-18.5% (-27.9 to 1.8) (P < 0.05) in motor d…
    2 context sentences
    Summary · context
    Twenty-nine of them were randomized into a GH group (n = 15) receiving 1 mg/m(2)/day GH or a non-GH-treated control group (n = 14).
    Summary · context
    At baseline and after 12 months of follow-up, analysis with Bayley Scales of Infant Development II (BSID-II) was performed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.